Laennec, 2 ml 10 pcs

Laennek is a new unique remedy, which promotes rejuvenation of the body and restoration of health, is an immunomodulator, hepatoprotector, promotes immunity.

The preparation exhibits immunomodulatory properties due to the ability to stimulate humoral immunity and increase the functional activity of phagocytes and natural killers. It increases bactericidal activity of leukocytes of peripheral blood which shows its ability to destroy invaded pathogen. Cytokines contained in the drug activate the metabolic and supervising functions of skin cells.

The biologically active substances contained in the hydrolyzate stimulate the regeneration (proliferation) of hepatocytes, exhibit detoxifying properties, reduce deposition of lipids and cholesterol in liver cells, increase the activity of tissue respiration, activate metabolism in the liver, reduce the intensity of connective tissue in the liver.

Indications

chronic recurrent herpes (as part of complex therapy);
atopic dermatitis of moderate and severe severity, incl. complicated (as part of complex therapy);
chronic liver diseases: steatohepatitis (alcoholic, metabolic and mixed etiology) – as monotherapy.

Pharmacological effect

Laennec is a new unique remedy that helps rejuvenate the body and restore health, is an immunomodulator, hepatoprotector, and helps improve immunity.

The drug exhibits immunomodulatory properties due to the ability to stimulate humoral immunity and increase the functional activity of phagocytes and natural killer cells. Increases the bactericidal activity of peripheral blood leukocytes, manifested in their ability to destroy the captured pathogen. The cytokines included in the drug activate the metabolic and supervisory functions of skin cells.

Biologically active substances contained in the hydrolyzate stimulate the regeneration (proliferation) of hepatocytes, exhibit detoxification properties, reduce the deposition of lipids and cholesterol in liver cells, increase the activity of tissue respiration, activate metabolism in the liver, and reduce the intensity of development of connective tissue in the liver.

Special instructions

According to currently available data, the drug can be prescribed to elderly people. However, given that physiological functions deteriorate in the elderly, the drug should be used under close supervision.

Use in pediatrics

Studies on the safety of Laennec in newborns (including premature infants) and minors have not been conducted. Use in children is not recommended.

Active ingredient

Human placenta hydrolyzate

Composition

Solution for injection.

1 ampoule contains:

Active substance:

human placenta hydrolyzate 112 mg

Excipients:

water for injections,

sodium hydroxide or hydrochloric acid (to adjust pH).

Contraindications

childhood;
pregnancy;
lactation period;
hypersensitivity to the drug.

It should be used with caution in patients with polyvalent allergies to drugs and in the elderly.

Side Effects

Side effects are observed in 3.7% of patients.

Clinically significant adverse reactions: allergic reactions are possible.

Other adverse events: pain at the injection site (2.56%), allergic reactions (redness, itching) (0.37%), numbness at the injection site (0.37%), gynecomastia (0.37%) – a cause-and-effect relationship with the administration of the drug has not been established.

Interaction

When mixing Laennec solution with other drugs that are strong bases (pH above 8.5), the activity of the drug is reduced.

To date, no other clinically significant drug interactions have been identified.

Overdose

Currently, no cases of overdose with Laennec have been reported.

Storage conditions

The drug should be stored in a place protected from light, out of reach of children, at a temperature of 18° to 25°C.

Shelf life

3 years.

Manufacturer

Japan Bio Products Co., Ltd., Japan